Comparsion of effects of Gonadotropin Releasing Hormon Agonists and Antagonists in ART cycles in infertile patients
Not Applicable
- Conditions
- infertility.female infertility
- Registration Number
- IRCT201109136626N3
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 120
Inclusion Criteria
infertile women older than 35 years who are conditions for art and have not any endocreean desease or hypertantion or polycistic ovarian syndrom(pcos) or history of endometriosis or any surgery of ovarian Exclusion criteria: Infertile women smaller than 35 years old or have any endocreean desease or hypertantion or polycistic ovarian syndrom(pcos) or history of endometriosis or any surgery of ovarian
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Rate of documented pregnancy. Timepoint: Two mounths after the end of intervention. Method of measurement: Sonography.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms differentiate GnRH agonists and antagonists in ART cycles for female infertility in patients over 35?
How does the use of GnRH agonists compare to antagonists in ART cycles for female infertility in terms of clinical outcomes in patients over 35?
Are there specific biomarkers that predict response to GnRH agonists versus antagonists in ART cycles for female infertility in patients over 35?
What are the known adverse events associated with GnRH agonists and antagonists in ART cycles for female infertility in patients over 35 and how are they managed?
What are the potential combination approaches involving GnRH agonists or antagonists in ART cycles for female infertility in patients over 35 and how do they compare to standard-of-care treatments?